Respirology最新文献_第10页

Pulmonary function testing in COPD: Anchoring clinical relevance. 慢性阻塞性肺病肺功能检测：锚定临床相关性。

IF 6.6 2区医学

Respirology Pub Date : 2025-02-01 Epub Date: 2024-12-08 DOI: 10.1111/resp.14867

Bruce R Thompson

引用次数: 0

Allele-specific micro-RNA-mediated regulation of ADAM33 in childhood allergic asthma. 等位基因特异性微 RNA 介导的 ADAM33 在儿童过敏性哮喘中的调控。

IF 6.6 2区医学

Respirology Pub Date : 2025-02-01 Epub Date: 2024-10-30 DOI: 10.1111/resp.14846

Xiang Wen, Juan Zhou, Heping Fang, Juan Li, Run Wang, Dan Zeng, Xiaohong Xie, Yu Deng, Luo Ren, Enmei Liu

{"title":"Allele-specific micro-RNA-mediated regulation of ADAM33 in childhood allergic asthma.","authors":"Xiang Wen, Juan Zhou, Heping Fang, Juan Li, Run Wang, Dan Zeng, Xiaohong Xie, Yu Deng, Luo Ren, Enmei Liu","doi":"10.1111/resp.14846","DOIUrl":"10.1111/resp.14846","url":null,"abstract":"Background and objective: A disintegrin and metalloprotease 33 (ADAM33) is associated with asthma susceptibility, and its genetic variations impact susceptibility and disease severity. However, the mechanisms remain unclear. This study aimed to investigate ADAM33 single nucleotide polymorphisms (SNPs) in childhood asthma susceptibility and explore their regulatory mechanisms.Methods: Eleven selected SNPs in ADAM33 were genotyped and identified the association with asthma susceptibility. In the validation cohort, we measured plasma sADAM33 levels and compared them with disease severity among children with different SNP genotypes. Computational predictions identified miRNAs targeting the SNP, and the impact of the SNP on miRNA regulation was confirmed using a dual luciferase reporter system. Finally, we validated the regulatory role of miRNAs on ADAM33 expression using an in vitro model with upregulated ADAM33 expression.Results: Only rs3918400 was associated with asthma susceptibility. In the validation cohort, children with allergic asthma exhibited higher plasma sADAM33 levels. Among asthmatic children, those with the rs3918400 CT/TT genotype had higher sADAM33 levels, poorer asthma control, more severe airway hyper-responsiveness, lower FEV1% and higher dust mite-specific IgE activity compared to those with the CC genotype. miR-3928-5p bound strongly to the rs3918400 C allele and effectively reduced ADAM33 protein expression in CC genotype cells. However, the binding affinity of miR-3928-5p to the T allele was weaker, resulting in diminished negative regulation of protein expression.Conclusion: The rs3918400 SNP affects the negative regulation of ADAM33 by miR-3928-5p, potentially participating in a complex interplay of processes related to childhood asthma susceptibility.","PeriodicalId":21129,"journal":{"name":"Respirology","volume":" ","pages":"113-123"},"PeriodicalIF":6.6,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142547041","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Lung Cancer in Non-Smokers. 非吸烟者的肺癌。

IF 6.6 2区医学

Respirology Pub Date : 2025-02-01 Epub Date: 2025-01-13 DOI: 10.1111/resp.14879

Akihiko Miyanaga, Masahiro Seike

引用次数: 0

Leading Women in Respiratory Care: Letter From Saudi Arabia. 呼吸护理领域的领军女性：来自沙特阿拉伯的信。

IF 6.6 2区医学

Respirology Pub Date : 2025-02-01 Epub Date: 2025-01-27 DOI: 10.1111/resp.14881

Fatma Almaghlouth, Amal Alamer

引用次数: 0

Usability of a smartphone application for patients with interstitial lung disease: Results from the Registry for Better Understanding of ILD (RE-BUILD) pilot study. 用于间质性肺病患者的智能手机应用程序的可用性：来自更好地了解ILD注册（RE-BUILD）试点研究的结果。

IF 6.6 2区医学

Respirology Pub Date : 2025-02-01 Epub Date: 2024-12-17 DOI: 10.1111/resp.14874

Laura M Glenn, Dan Jackson, Carly Barton, Doris Lan, Lisa Fuhrmeister, Karen Symons, Louise Turnour, Ben Tefay, Anne E Holland, Nicole S L Goh, Lauren K Troy, Mark Brooke, Ian N Glaspole, Tamera J Corte

{"title":"Usability of a smartphone application for patients with interstitial lung disease: Results from the Registry for Better Understanding of ILD (RE-BUILD) pilot study.","authors":"Laura M Glenn, Dan Jackson, Carly Barton, Doris Lan, Lisa Fuhrmeister, Karen Symons, Louise Turnour, Ben Tefay, Anne E Holland, Nicole S L Goh, Lauren K Troy, Mark Brooke, Ian N Glaspole, Tamera J Corte","doi":"10.1111/resp.14874","DOIUrl":"10.1111/resp.14874","url":null,"abstract":"Background and objective: Digital technologies offer opportunities for remote monitoring, increased patient engagement and incorporation of patient-reported outcome measures (PROMs) into interstitial lung disease (ILD) care and research. This study evaluated the usability and patient experience of the RE-BUILD (Registry for Better Understanding of ILD) application, an ILD-specific smartphone app.Methods: Patients with ILD aged ≥18 years were recruited from three tertiary ILD centres to use the RE-BUILD app for 6 months. The mHealth App Usability Questionnaire (MAUQ) was evaluated at 1, 3 and 6 months and patients received monthly prompts to enter clinical and PROM data. Qualitative interviews regarding patient experience were performed in a subset of 10.Results: Fifty patients, with mean age 66.9 ± 10.3 years, 25 (50%) female were included. Participants used the app for a median of 48 (IQR 21-178.3) sessions, equivalent to 8 sessions (IQR 3.5-29.71) per month. Median number of days that the app was accessed was 37 (IQR 14-96.8), with 13 (26%) patients using the app >30 times per month. The most accessed app feature was physical activity, followed by 'air quality'. Participants agreed or strongly agreed that the app was easy to use (76.0%) easy to learn to use (79.8%) and well-organized with accessible information (74.8%). The median overall MAUQ score for usability was 5.69 (IQR 5.03-6.19). There was also a high rate of engagement with app functionalities.Conclusion: RE-BUILD is a usable and intuitive platform for self-monitoring and data collection in ILD. Patients report a high degree of satisfaction and have provided valuable feedback for its further development.","PeriodicalId":21129,"journal":{"name":"Respirology","volume":" ","pages":"147-157"},"PeriodicalIF":6.6,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142847693","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Environmental impact of inhaled medicines: A Thoracic Society of Australia and New Zealand position statement. 吸入药物对环境的影响：澳大利亚和新西兰胸腔协会立场声明。

IF 6.6 2区医学

Respirology Pub Date : 2025-02-01 Epub Date: 2024-11-13 DOI: 10.1111/resp.14852

Danielle F Wurzel, Brett D Montgomery, Natalie Anderson, Elena K Schneider-Futschik, Johnson George, Sinthia Bosnic-Anticevich, Emily Stone, Robert J Hancox, James Fingleton, Stephanie Kuek, Helen Tope, John Blakey

{"title":"Environmental impact of inhaled medicines: A Thoracic Society of Australia and New Zealand position statement.","authors":"Danielle F Wurzel, Brett D Montgomery, Natalie Anderson, Elena K Schneider-Futschik, Johnson George, Sinthia Bosnic-Anticevich, Emily Stone, Robert J Hancox, James Fingleton, Stephanie Kuek, Helen Tope, John Blakey","doi":"10.1111/resp.14852","DOIUrl":"10.1111/resp.14852","url":null,"abstract":"Globally, more than 1.2 billion inhalers are purchased for asthma and chronic obstructive pulmonary disease (COPD) annually. In Australia and New Zealand, pressurized metered dose inhalers (pMDIs) are the leading delivery device prescribed and pMDI salbutamol can be purchased over the counter in Australia. These inhalers are a major contributor to healthcare related greenhouse gases. This is due to the propellants that they currently contain which have extremely high global warming potential (GWP). In this position paper, we report the findings of a Thoracic Society of Australia and New Zealand (TSANZ) working group on the environmental impact of inhaled respiratory medicines. We reviewed the use of inhaled medicines in Australia and New Zealand and their contribution to climate change and other environmental degradation. We propose strategies for health professionals and consumers to reduce environmental impact in the management of airway diseases. These include accurate diagnosis to avoid unnecessary treatment, better disease control to minimize the need for reliever therapy and actively choosing inhaler devices with lower environmental impacts when clinically appropriate. Inhaler selection should be tailored to the individual, aiming to achieve the best possible clinical outcome. Choosing an appropriate inhaler for an individual involves consideration of factors such as dexterity, inspiratory capacity and cost. In our current climate emergency and with the availability of lower carbon alternatives, health professionals should also consider environmental impact.","PeriodicalId":21129,"journal":{"name":"Respirology","volume":" ","pages":"101-112"},"PeriodicalIF":6.6,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11788458/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142627009","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Reassessing pyrazinamide: Disentangling the myth of dose-dependent hepatotoxicity and advancing dosing strategies in elderly tuberculosis patients. 重新评估吡嗪酰胺：打破剂量依赖性肝毒性的神话，改进老年肺结核患者的用药策略。

IF 6.6 2区医学

Respirology Pub Date : 2025-02-01 Epub Date: 2024-12-17 DOI: 10.1111/resp.14872

Samadhi Patamatamkul

引用次数: 0

The potential lipid biomarker 5-HETE for acute exacerbation identified by metabolomics in patients with idiopathic pulmonary fibrosis. 通过代谢组学鉴定特发性肺纤维化患者急性加重的潜在脂质生物标志物 5-HETE。

IF 6.6 2区医学

Respirology Pub Date : 2025-02-01 Epub Date: 2024-12-16 DOI: 10.1111/resp.14866

Yichao Zhao, Yanchen Shi, Ji Zhang, Huizhe Zhang, Zimu Wang, Shufei Wu, Mingrui Zhang, Mengying Liu, Xu Ye, Huimin Gu, Cheng Jiang, Xiaoling Ye, Huihui Zhu, Qi Li, Xinmei Huang, Mengshu Cao

{"title":"The potential lipid biomarker 5-HETE for acute exacerbation identified by metabolomics in patients with idiopathic pulmonary fibrosis.","authors":"Yichao Zhao, Yanchen Shi, Ji Zhang, Huizhe Zhang, Zimu Wang, Shufei Wu, Mingrui Zhang, Mengying Liu, Xu Ye, Huimin Gu, Cheng Jiang, Xiaoling Ye, Huihui Zhu, Qi Li, Xinmei Huang, Mengshu Cao","doi":"10.1111/resp.14866","DOIUrl":"10.1111/resp.14866","url":null,"abstract":"Background and objective: Acute exacerbation (AE) is often the fatal complication of idiopathic pulmonary fibrosis (IPF). Emerging evidence indicates that metabolic reprogramming and dysregulation of lipid metabolism are distinctive characteristics of IPF. However, the lipid metabolic mechanisms that underlie the pathophysiology of AE-IPF remain elusive.Methods: Serum samples for pilot study were collected from 34 Controls, 37 stable IPF (S-IPF) cases and 41 AE-IPF patients. UHPLC-MS/MS was utilized to investigate metabolic variations and identify lipid biomarkers in serum. ELISA, quantitative PCR and western blot were employed to validate the identified biomarkers.Results: There were 32 lipid metabolites and 5 lipid metabolism pathways enriched in all IPF patients compared to Controls. In AE-IPF versus S-IPF, 19 lipid metabolites and 12 pathways were identified, with 5-hydroxyeicosatetraenoic Acid (5-HETE) significantly elevated in AE-IPF. Both in internal and external validation cohorts, the serum levels of 5-HETE were significantly elevated in AE-IPF patients compared to S-IPF subjects. Consequently, the indicators related to 5-HETE in lipid metabolic pathway were significantly changed in AE-IPF patients compared with S-IPF cases in the lung tissues. The serum level of 5-HETE was significantly correlated with the disease severity (CT score and PaO2/FiO2 ratio) and survival time. Importantly, the receiver operating characteristic (ROC) curve, Kaplan-Meier analysis and Multivariate Cox regression analysis demonstrated that 5-HETE represents a promising lipid biomarker for the diagnosis and prognosis of AE-IPF.Conclusion: Our study highlights lipid reprogramming as a novel therapeutic approach for IPF, and 5-HETE may be a potential biomarker of AE-IPF patients.","PeriodicalId":21129,"journal":{"name":"Respirology","volume":" ","pages":"158-167"},"PeriodicalIF":6.6,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142839157","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Response to 'Reassessing pyrazinamide: Disentangling the myth of dose-dependent hepatotoxicity and advancing dosing strategies in elderly tuberculosis patients'. 对 "重新评估吡嗪酰胺：打破剂量依赖性肝毒性的神话，推进老年肺结核患者的用药策略 "的回应。

IF 6.6 2区医学

Respirology Pub Date : 2025-02-01 Epub Date: 2024-12-17 DOI: 10.1111/resp.14873

Jumpei Taniguchi, Shotaro Aso, Hideo Yasunaga

引用次数: 0

Diffusion capacity and static hyperinflation as markers of disease progression predict 3-year mortality in COPD: Results from COSYCONET. 作为疾病进展标志物的扩散能力和静态过度充气可预测慢性阻塞性肺病的 3 年死亡率：COSYCONET 的研究结果。

IF 6.6 2区医学

Respirology Pub Date : 2025-02-01 Epub Date: 2024-10-24 DOI: 10.1111/resp.14843

Hendrik Pott, Barbara Weckler, Swetlana Gaffron, Roman Martin, Dieter Maier, Peter Alter, Frank Biertz, Tim Speicher, Wilhelm Bertrams, Anna Lena Jung, Katrin Laakmann, Dominik Heider, Miel Wouters, Claus F Vogelmeier, Bernd Schmeck

{"title":"Diffusion capacity and static hyperinflation as markers of disease progression predict 3-year mortality in COPD: Results from COSYCONET.","authors":"Hendrik Pott, Barbara Weckler, Swetlana Gaffron, Roman Martin, Dieter Maier, Peter Alter, Frank Biertz, Tim Speicher, Wilhelm Bertrams, Anna Lena Jung, Katrin Laakmann, Dominik Heider, Miel Wouters, Claus F Vogelmeier, Bernd Schmeck","doi":"10.1111/resp.14843","DOIUrl":"10.1111/resp.14843","url":null,"abstract":"Background and objective: Chronic obstructive pulmonary disease (COPD) exhibits diverse patterns of disease progression, due to underlying disease activity. We hypothesized that changes in static hyperinflation or KCO % predicted would reveal subgroups with disease progression unidentified by preestablished markers (FEV1, SGRQ, exacerbation history) and associated with unique baseline biomarker profiles. We explored 18-month measures of disease progression associated with 18-54-month mortality, including changes in hyperinflation parameters and transfer factor, in a large German COPD cohort.Methods: Analysing data of 1364 patients from the German observational COSYCONET-cohort, disease progression and improvement patterns were assessed for their impact on mortality via Cox hazard regression models. Association of biomarkers and COPD Assessment test items with phenotypes of disease progression or improvement were evaluated using logistic regression and random forest models.Results: Increased risk of 18-54-month mortality was linked to decrease in KCO % predicted (7.5% increments) and FEV1 (20 mL increments), increase in RV/TLC (2% increments) and SGRQ (≥6 points), and an exacerbation grade of 2 at 18 months. Decrease in KCO % predicted ≥7.5% and an increase of RV/TLC ≥2% were the most frequent measures of 18-month disease progression occurring in ~52% and ~46% of patients, respectively. IL-6 and CRP thresholds exhibited significant associations with medium- and long-term disease measures.Conclusion: In a multicentric cohort of COPD, new markers of current disease activity predicted mid-term mortality and could not be anticipated by baseline biomarkers.","PeriodicalId":21129,"journal":{"name":"Respirology","volume":" ","pages":"134-146"},"PeriodicalIF":6.6,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11788467/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142506931","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0